Figure 4.

Multivalent antibody constructs for lymphoma immunotherapy. Numerous polyspecific antibody constructs with a range of binding valencies have been developed, and several formats are in advanced stages of development for lymphoma. Bispecific antibodies (BsAbs) are a very common format, with multiple derivatives, including DuoMabs and multivalent ligands incorporating additional antigen-binding fragments (Fabs). Bispecific T-cell engagers (BiTEs) and tandem diabodies (TandAbs) are physically smaller targeting ligands based on the careful fusion and folding of single-chain variable fragments (scFvs). Here, red and blue elements distinguish scaffold components that correlate with binding to two distinct target epitopes.